- Michael Aschner, Vanderbilt University
- Phil Biggin, University of Oxford
- Lucio Guido Costa, University of Washington
- David H Farb, Boston University School of Medicine
- Giorgio Palu, University of Padova
- Christopher Morrey, BioMed Central
A pre-exposure trial in African women does not suggest a significant relationship between TDF-FTC and creatinine or phosphorus toxicities, but those randomized to TDF-FTC have higher rates of mild to moderate ALT/AST toxicities, especially those with prior hepatitis B virus exposure.
The development of a quantum mechanistic model predicts the skin sensitization potential of mechanistically hard-to-be-classified aniline and phenol chemicals and could be useful for the skin sensitization potential predictions of a subset of FDA approved drugs.
Thromboxane A2 receptor (TXA2R) activation does not induce changes in hypertrophy or genes associated with hypertrophy but is capable of inducing cell death and DNA fragmentation suggesting it may play a role in mediating cell death in cardiomyocytes.
Multivariable analysis suggests that high-volume hydration and magnesium supplementation may reduce the renal toxicity induced by cisplatin-based chemotherapy in patients with lung cancer and a low-volume magnesium regimen may be considered for patients with adequate renal function.
Evaluation of the substrate profiles of various native and engineered mammalian arylamine N-acetyltransferases (NATs) in the context of their structures highlights the features which influence substrate selectivity in mammals.
Marta Sidoryk-Wegrzynowicz and Michael AschnerBMC Pharmacology and Toxicology 2013, 14:23 (18 April 2013)
BMC Pharmacology and Toxicology 2015, 16:10
News from the web
- 25 April 2015
- Drug research enhanced by fragment screening libraries
- 25 April 2015
- Scientists X-ray anti-inflammatory drug candidates
- 23 April 2015
- ESCMID warns that Europe may surpass one million deaths due to ineffective antibiotics by 2025
BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials.
BMC Pharmacology and Toxicology is part of the BMC series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We offer an efficient, fair and friendly peer review service, and are committed to publishing all sound science, provided that there is some advance in knowledge presented by the work.
BMC series - open, inclusive and trusted.
Section Editor's profile
David H Farb is Professor and Chair of the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine. He is Principal Investigator and Director of the Laboratory of Molecular Neurobiology and Director of the university-wide NIGMS training program in Biomolecular Pharmacology. A renowned neuropharmacologist, his research integrates existing electrophysiological, behavioral, pharmacological, and molecular genetic technologies in a novel systems-level platform to establish a molecular dissection of spatial memory. Dr Farb is Section Editor for 'Basic pharmacology' and you can read more about the key issues in this field and his aspirations for the journal in his recent interview here.
"Pharmacology is a powerful interdisciplinary science providing an essential link between hypotheses developed from molecular, systems, and clinical models with the ultimate goal of improving human health. Our journal publishes timely research describing advances in a broad range of disciplines that combine novel approaches within a framework of rigorous scientific research."
BMC series blog
- 15 April 2015
- Stillbirth: the elephant in the room
BMC Pharmacology and Toxicology assimilated the Editorial boards and history of BMC Pharmacology and BMC Clinical Pharmacology on fusion of the journals in 2012. The full archive of BMC Pharmacology is available from its own archive website, and the objectives and aspirations of the merged journal are explained in the editorial that accompanied the fusion. The full archive of BMC Clinical Pharmacology is available here.